EU/3/11/870

About

On 13 May 2011, orphan designation (EU/3/11/870) was granted by the European Commission to Salupont Consulting Ltd, United Kingdom, for S-nitrosoglutathione for the treatment of pre-eclampsia.

The sponsorship was transferred to Salupont Italia S.r.l., Italy in May 2019.

Key facts

Active substance
S-Nitrosoglutathione
Disease / condition
Treatment of pre-eclampsia
Date of first decision
13/05/2011
Outcome
Positive
EU designation number
EU/3/11/870

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Salupont Italia S.r.l.
Piazza Della Repubblica 12
20124 Milan
Italy
Tel: +39 0236 586499
E-mail: drees@salupontitalia.it

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating